Efstathios Kastritis, MD, on Main Findings From the ANDROMEDA Study in Newly Diagnosed AL Amyloidosis

Video

The expert discussed key details from the phase 3 ANDROMEDA trial presented at the 2021 ASCO Annual Meeting.

CancerNetwork® spoke with Efstathios Kastritis, MD, professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting, to discuss some of the key outcomes from the phase 3 ANDROMEDA trial (NCT03201965) investigating subcutaneous daratumumab (DARA; Darzalex) plus bortezomib (Velcade), cyclophosphamide, and dexamethasone (VCd) for patients with newly diagnosed light chain (AL) amyloidosis.

Transcription:

In the ANDROMEDA study, patients with newly diagnosed AL amyloidosis [who] had stage 1, 2, or 3 cardiac disease were randomized to receive either the standard therapy, which is a combination of bortezomib, cyclophosphamide, and dexamethasone—also called VCd—compared [with] VCd plus subcutaneous daratumumab (DARA) for 6 cycles, followed by daratumumab maintenance for up to 24 cycles.

In the updated analysis that will [be presented at] ASCO, the complete hematologic response rate in the DARA-VCd arm has further improved to 59% versus 19% for the old standard VCd. There has been a substantial improvement in the complete hematologic response rates across all the subgroups of patients [who] were evaluated, including patients with more advanced cardiac disease, and also patients with translocation (11;14), or older or younger patients.

In the updated analysis that we present [at] ASCO, we see that at [the] 12-month landmark, the organ response rates have also improved.We have a significant improvement in the cardiac response rates with DARA-VCd, which increased from 42% to 57% versus 28% for the VCd arm, so we have a doubling of the cardiac responses. Also, we see a doubling of renal responses, both at 6- and at 12-month [mark] for DARA-VCd versus VCd. These are very important outcomes for our patients with AL amyloidosis.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. J Clin Oncol. 2021;39(suppl 15):8003. doi: 10.1200/JCO.39.15_suppl.8003

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content